Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 15/20 | 0.48 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 6/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4158631 | 0.92 | PDE10A (0.43) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL4765581 | 0.88 | PDE10A (0.61) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL4159440 | 0.83 | PDE10A (0.50) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL4150501 | 0.76 | PDE10A (0.77) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL4162873 | 0.74 | PDE10A (0.44) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL4765580 | 0.73 | PDE10A (0.58) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL4153844 | 0.72 | PDE10A (0.59) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL12970432 | 0.70 | PDE10A (0.60) | PDE10A | |
| SCHEMBL4791752 | 0.69 | PDE10A (0.67) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL4158252 | 0.69 | PDE10A (0.66) | PDE10ALGALS3PDE4DPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176829-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER INC | 2009-07-09 | — | — | US | claimed |
| WO-2007129183-A2 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-11-15 | — | — | WO | claimed |
| US-20090176829-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER INC | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176829-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PDE12, PDE7A, PDE9A | PDE10A 4/4885LGALS3 4543/4885PDE4D 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.